Do you want to visit this external website and leave amgenpro.com.au?
You are now leaving this Amgen Australia website. Amgen Australia assumes no responsibility for, and exercises no control over, the organizations, opinions, or accuracy of the information on the server or website you are redirected to.
Do you want to visit this external website and leave amgenpro.com.au?
You are now leaving this Amgen Australia website. Amgen Australia assumes no responsibility for, and exercises no control over, the organizations, opinions, or accuracy of the information on the server or website you are redirected to.
You can paste this link into an email or message to share this resource with your patient.
Multiple myeloma is a malignant plasma cell disorder accounting for around 1% of all cancers and 10% of haematologic malignancies in Australia. It predominantly affects older adults and is characterized by clonal plasma cell proliferation, monoclonal protein production, and end-organ damage. Advances in proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies have significantly improved survival, though the disease remains incurable and relapsing.
AmgenPro is intended for healthcare professionals in Australia
Login or create an AmgenPro account to access the latest updates on our products, medical resources and patient programs.